Arbutus Biopharma Investor Relations Material
Latest events
Status Update
Arbutus Biopharma
Q2 2025
6 Aug, 2025
Q1 2025
14 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arbutus Biopharma Corporation
Access all reports
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for viral diseases. The company utilizes its expertise in RNA interference (RNAi) technology and small molecule development to address diseases such as chronic hepatitis B. Arbutus conducts research and development to advance its proprietary drug candidates and explore combination treatment approaches. The company is headquartered in Warminster, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ABUS
Country
🇺🇸 United States